Default Mode Network Connectivity and Nocebo Responses in Migraine: A Functional MRI Study
NCT07720895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-07-22
Summary
People with migraine sometimes experience symptoms because they expect a treatment to cause side effects. This is known as the "nocebo effect". Unlike a drug side effect, a nocebo effect is triggered by negative expectations rather than by the treatment itself. Nocebo effects can reduce patients' confidence in treatment and may lead them to stop taking medications that could help control their migraine. Understanding why some people are more likely to experience nocebo effects could help healthcare professionals improve treatment discussions and support long-term treatment adherence.
The aim of this study was to investigate whether changes in brain activity are associated with nocebo responses in people with migraine. Researchers focused on the "default mode network" (DMN), a group of interconnected brain regions involved in self-reflection, emotions, memory, and expectations. Because expectations play an important role in nocebo effects, the researchers examined whether communication within this brain network changed during a nocebo challenge.
Forty adults with migraine were recruited from the Headache Clinic of Aeginition Hospital, National and Kapodistrian University of Athens, between October 2019 and February 2023. All participants underwent magnetic resonance imaging (MRI) and resting-state functional MRI (rs-fMRI), a technique that measures communication between brain regions while a person is resting. Participants were then randomly assigned to one of three groups. One group received an intravenous saline infusion together with the suggestion that they might experience numbness. A second group received only the same verbal suggestion, without the saline infusion. A third group received no intervention. Thirty minutes later, participants reported whether they had experienced numbness before undergoing a second brain scan. Participants also completed a questionnaire measuring their susceptibility to nocebo effects. Four participants were excluded because excessive movement affected the quality of their MRI scans, leaving 36 participants for the final analysis.
This study investigated whether changes in DMN connectivity were associated with the nocebo challenge and whether these changes differed between participants who did and did not report numbness. By identifying brain mechanisms involved in nocebo responses, this research may improve our understanding of why some people are more susceptible than others. Although the study was exploratory and included a relatively small number of participants, its findings may contribute to future strategies that help clinicians identify patients at greater risk of nocebo responses, communicate more effectively about treatment, and improve adherence to migraine therapies. Larger studies are needed to confirm these findings before they can be applied in routine clinical practice.
Conditions
- Migraine
- Nocebo Effects
Interventions
- OTHER
-
intravenous saline infusion
An intravenous "contrast agent" (10 ml of normal saline 0.9%) was administrated, and participants were informed that they will be given an intravenous "contrast agent", needed for the second rs- fMRI scan, that may numb one side of their body.
- BEHAVIORAL
-
Negative verbal suggestion
Participants did not receive any "contrast agent", but were informed that during the second fMRI scan, "they may feel numbness", thus they received negative verbal suggestion only.
- OTHER
-
No intervention
This group did not receive any "contrast agent" or negative verbal suggestion
Sponsors & Collaborators
-
Ioanna Spanou
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-22
- Primary Completion
- 2023-10-22
- Completion
- 2023-10-22
Countries
- Greece
Study Locations
More Related Trials
-
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188 ·Status: RECRUITING ·Phase: NA
-
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
NCT03308968 ·Status: COMPLETED ·Phase: PHASE3
-
Neurophysiology of Prophylactic Treatment in Migraine
NCT04019496 ·Status: COMPLETED
-
Functional MRI (fMRI) in CGRP Induced Migraine
NCT00363532 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
NCT04041284 ·Status: COMPLETED ·Phase: PHASE4
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847 ·Status: RECRUITING ·Phase: PHASE2
-
The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras
NCT01080287 ·Status: COMPLETED
-
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
NCT01970943 ·Status: COMPLETED ·Phase: NA
-
The Prevalence of Osmophobia in Migraine and Tension-Type Headache Patients and Its Association With Migraine Symptoms Over a Period of 6 Months
NCT07329127 ·Status: COMPLETED
-
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782 ·Status: COMPLETED ·Phase: PHASE2
-
Pain Control in Episodic and Chronic Migraine
NCT06599905 ·Status: COMPLETED ·Phase: NA
-
Expectancies in Migraine Patients
NCT06633991 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
NCT00123201 ·Status: COMPLETED ·Phase: PHASE2
-
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
NCT01899040 ·Status: COMPLETED ·Phase: NA
-
Migraine in Adolescents
NCT05654012 ·Status: RECRUITING ·Phase: NA
-
Efficacy, Tolerability, and Safety Study of DFN-15
NCT03006276 ·Status: COMPLETED ·Phase: PHASE3
-
Botox Injection in Treatment of Chronic Migraine
NCT02259075 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Brief Interventions in Chronic Migraine
NCT05979337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
NCT04102995 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Tolerability, and Safety of DFN-15
NCT03009019 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Glymphatic System in Migraine
NCT05907655 ·Status: RECRUITING
-
Headache Provocation of People Who Are Unable to Have Headache
NCT04217668 ·Status: COMPLETED ·Phase: NA
-
Near Death Experience (NDE) and Migraine
NCT02854930 ·Status: UNKNOWN
-
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649 ·Status: COMPLETED ·Phase: PHASE4
-
The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab
NCT06244823 ·Status: RECRUITING ·Phase: PHASE4